Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases. Through our proprietary platforms, deep scientific expertise, and global partnerships, we build and manage a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

October 23, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 23, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

October 19, 2026

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma